{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T21:49:07Z","timestamp":1793828947993,"version":"4.6.1"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T00:00:00Z","timestamp":1710892800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Triazole antifungal agents are widely used to treat and prevent systemic mycoses. With wide clinical use, the number of reported adverse events has gradually increased. The aim of this study was to analyze the cardiac disorders associated with TAAs (fluconazole, voriconazole, itraconazole, posaconazole and isavuconazole) based on data from the US Food and Drug Administration Adverse Event Reporting System FDA Adverse Event Reporting System.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Data were extracted from the FAERS database between the first quarter of 2004 and third quarter of 2022. The clinical characteristics in TAA-associated cardiac AE reports were analyzed. Disproportionality analysis was performed to evaluate the potential association between AEs and TAAs using the reporting odds ratio (ROR) and proportional reporting ratio (PRR).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among 10,178,522 AE reports, 1719 reports were TAA-associated cardiac AEs as primary suspect drug. Most reports were related to fluconazole (38.34%), voriconazole (28.56%) and itraconazole (26.76%). Itraconazole (N = 195, 42.39%) and isavuconazole (N = 2, 14.29%) had fewer serious outcome events than three other drugs including fluconazole, voriconazole, and posaconazole. 13, 11, 26, 5 and 1 signals were detected for fluconazole, voriconazole, itraconazole, posaconazole and isavuconazole, respectively. The number of new signals unrecorded in the drug label was 9, 2, 13, 2 and 0 for fluconazole, voriconazole, itraconazole, posaconazole and isavuconazole, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Isavuconazole might be the safest of the five TAAs for cardiac AEs. TAA-associated cardiac disorders may result in serious adverse outcomes. Therefore, in addition to AEs on the drug label, we should pay attention to new AEs unrecorded on the drug label during the clinical use of TAAs.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2024.1255918","type":"journal-article","created":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T05:05:47Z","timestamp":1710911147000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":15,"title":["Evaluating cardiac disorders associated with triazole antifungal agents based on the US Food and Drug Administration Adverse Event reporting system database"],"prefix":"10.3389","volume":"15","author":[{"given":"Jinhua","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shijun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijiang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuicui","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenzhou","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,3,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"59","DOI":"10.2174\/1574886312666171003110753","article-title":"Itraconazole induced congestive heart failure, a case study","volume":"13","author":"Abraham","year":"2018","journal-title":"Curr. Drug. Saf."},{"key":"B2","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1111\/bcp.15178","article-title":"Active-comparator restricted disproportionality analysis for pharmacovigilance signal detection studies of chronic disease medications: an example using sodium\/glucose cotransporter 2 inhibitors","volume":"89","author":"Alkabbani","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1080\/17425255.2017.1391213","article-title":"Pharmacogenomics of triazole antifungal agents: implications for safety, tolerability and efficacy","volume":"13","author":"Amsden","year":"2017","journal-title":"Expert. Opin. Drug. Metab. Toxicol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"160026","DOI":"10.1038\/sdata.2016.26","article-title":"A curated and standardized adverse drug event resource to accelerate drug safety research","volume":"3","author":"Banda","year":"2016","journal-title":"Sci. Data."},{"key":"B5","doi-asserted-by":"publisher","first-page":"4421","DOI":"10.1111\/bcp.14868","article-title":"Pharmacovigilance-based drug repurposing: the search for inverse signals via OpenVigil identifies putative drugs against viral respiratory infections","volume":"87","author":"B\u00f6hm","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"754","DOI":"10.3760\/cma.j.cn112138-20200627-00624","article-title":"The Chinese guidelines for the diagnosis and treatment of invasive fungal disease in patients with hematological disorders and cancers (the 6th revision)","volume":"59","year":"2020","journal-title":"Zhonghua. Nei. Ke. Za. Zhi."},{"key":"B7","doi-asserted-by":"publisher","first-page":"e405","DOI":"10.1016\/S1473-3099(19)30312-3","article-title":"Global guideline for the diagnosis and management of mucormycosis: an initiative of the European confederation of medical mycology in cooperation with the mycoses study group education and research consortium","volume":"19","author":"Cornely","year":"2019","journal-title":"Lancet. Infect. Dis."},{"key":"B8","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1097\/CRD.0000000000000436","article-title":"Kounis syndrome: a review of an uncommon cause of acute coronary syndrome","volume":"31","author":"Douedi","year":"2023","journal-title":"Cardiol. Rev."},{"key":"B9","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1111\/j.1365-2710.2007.00812.x","article-title":"Inherited long QT syndrome revealed by antifungals drug-drug interaction","volume":"32","author":"Eiden","year":"2007","journal-title":"J. Clin. Pharm. Ther."},{"key":"B10","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1111\/pace.13296","article-title":"Acquired long QT syndrome and torsade de pointes","volume":"41","author":"El-Sherif","year":"2018","journal-title":"Pacing. Clin. Electrophysiol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s00702-020-02276-x","article-title":"Drug safety profiles in geriatric patients with Parkinson's disease using the FORTA (Fit fOR the Aged) classification: results from a mono-centric retrospective analysis","volume":"128","author":"Greten","year":"2021","journal-title":"J. Neural. Transm. (Vienna)"},{"key":"B12","doi-asserted-by":"publisher","first-page":"00102","DOI":"10.1016\/S1473-3099(24)00102-6","article-title":"Global incidence and mortality of severe fungal disease","author":"Ikuta","year":"2024","journal-title":"Lancet. Infect. Dis."},{"key":"B13","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/imj.15586","article-title":"Consensus guidelines for antifungal stewardship, surveillance and infection prevention, 2021","volume":"51","author":"Khanina","year":"2021","journal-title":"Intern. Med. J."},{"key":"B14","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.2165\/11596540-000000000-00000","article-title":"Triazole antifungal agents in invasive fungal infections: a comparative review","volume":"71","author":"Lass-Fl\u00f6rl","year":"2011","journal-title":"Drugs"},{"key":"B15","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/S1473-3099(16)00071-2","article-title":"Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis","volume":"16","author":"Marty","year":"2016","journal-title":"Lancet. Infect. Dis."},{"key":"B16","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1111\/myc.12731","article-title":"Isavuconazole shortens the QTc interval","volume":"61","author":"Mellinghoff","year":"2018","journal-title":"Mycoses"},{"key":"B17","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1093\/jac\/dky392","article-title":"Real-world implications of QT prolongation in patients receiving voriconazole and amiodarone","volume":"74","author":"Mourad","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"B18","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.cmi.2023.12.006","article-title":"Risk factors, mortality, and predictors of survival in COVID-19-associated pulmonary mucormycosis: a multicentre retrospective study from India","volume":"30","author":"Muthu","year":"2024","journal-title":"Clin. Microbiol. Infect."},{"key":"B19","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1111\/j.1465-3362.2009.00128.x","article-title":"Itraconazole-induced torsade de pointes in a patient receiving methadone substitution therapy","volume":"28","author":"NoorZurani","year":"2009","journal-title":"Drug. Alcohol. Rev."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1086\/508873","article-title":"Antimicrobial-associated QT interval prolongation: pointes of interest","volume":"43","author":"Owens","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"B21","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.rmr.2010.08.014","article-title":"Acute cardiac failure due to itraconazole","volume":"28","author":"Paleiron","year":"2011","journal-title":"Rev. Mal. Respir."},{"key":"B22","doi-asserted-by":"publisher","first-page":"295","DOI":"10.12659\/ajcr.896946","article-title":"Long QT syndrome leading to multiple cardiac arrests after posaconazole administration in an immune-compromised patient with sepsis: an unusual case report","volume":"17","author":"Panos","year":"2016","journal-title":"Am. J. Case. Rep."},{"key":"B23","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the infectious diseases society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.3390\/ph15081007","article-title":"Pharmaceutical prevention and management of cardiotoxicity in hematological malignancies","volume":"15","author":"Perpinia","year":"2022","journal-title":"Pharm. (Basel)"},{"key":"B25","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1002\/pds.615","article-title":"The role of databases in drug post-marketing surveillance","volume":"10","author":"Rodriguez","year":"2001","journal-title":"Pharmacoepidemiol. Drug. Saf."},{"key":"B26","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol. Drug. Saf."},{"key":"B27","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1159\/000073224","article-title":"Inhibition of cytochrome P450 3A: relevant drug interactions in gastroenterology","volume":"68","author":"Sagir","year":"2003","journal-title":"Digestion"},{"key":"B28","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA adverse event reporting system","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int. J. Med. Sci."},{"key":"B29","doi-asserted-by":"publisher","first-page":"11","DOI":"10.21542\/gcsp.2017.11","article-title":"Torsade de pointes and systemic azole antifungal agents: analysis of global spontaneous safety reports","volume":"2017","author":"Salem","year":"2017","journal-title":"Glob. Cardiol. Sci. Pract."},{"key":"B30","first-page":"36","article-title":"Itraconazole-induced hypokalemia in a patient with pulmonary aspergilloma","volume":"37","author":"Sasaki","year":"1999","journal-title":"Nihon, Kokyuki, Gakkai, Zasshi."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1161\/CIRCULATIONAHA.111.080887","article-title":"Clinical and genetic determinants of torsade de pointes risk","volume":"125","author":"Sauer","year":"2012","journal-title":"Circulation"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1016\/j.jacc.2015.12.063","article-title":"Predicting the unpredictable: drug-induced QT prolongation and Torsades de Pointes","volume":"67","author":"Schwartz","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.chest.2023.09.012","article-title":"Epidemiology of COVID 19-associated mucormycosis in the United States","volume":"165","author":"Sharma","year":"2024","journal-title":"Chest"},{"key":"B34","doi-asserted-by":"publisher","first-page":"20420986221127503","DOI":"10.1177\/20420986221127503","article-title":"Therapeutic drug monitoring and safety evaluation of voriconazole in the treatment of pulmonary fungal diseases","volume":"13","author":"Shen","year":"2022","journal-title":"Ther. Adv. Drug. Saf."},{"key":"B35","doi-asserted-by":"publisher","first-page":"17019","DOI":"10.1038\/s41598-022-21260-x","article-title":"Detection and categorization of severe cardiac disorders based solely on heart period measurements","volume":"12","author":"Shinomoto","year":"2022","journal-title":"Sci. Rep."},{"key":"B36","doi-asserted-by":"publisher","first-page":"e961","DOI":"10.1097\/MJT.0000000000000113","article-title":"Fluconazole-induced type 1 Kounis syndrome","volume":"23","author":"Singh Mahal","year":"2016","journal-title":"Am. J. Ther."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1093\/jac\/dkad143","article-title":"Primary prophylaxis of invasive fungal diseases in patients with haematological malignancies: 2022 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO)","volume":"78","author":"Stemler","year":"2023","journal-title":"J. Antimicrob. Chemother."},{"key":"B38","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.mayocpiqo.2020.05.006","article-title":"The many faces of itraconazole cardiac toxicity","volume":"4","author":"Teaford","year":"2020","journal-title":"Mayo. Clin. Proc. Innov. Qual. Outcomes."},{"key":"B39","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.cmi.2018.01.002","article-title":"Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline","volume":"24","author":"Ullmann","year":"2018","journal-title":"Clin. Microbiol. Infect."},{"key":"B40","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s00540-017-2314-6","article-title":"Acquired prolongation of QT interval as a risk factor for torsade de pointes ventricular tachycardia: a narrative review for the anesthesiologist and intensivist","volume":"31","author":"Uvelin","year":"2017","journal-title":"J. Anesth."},{"key":"B41","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions","volume":"11","author":"van Puijenbroek","year":"2002","journal-title":"Pharmacoepidemiol. Drug. Saf."},{"key":"B42","doi-asserted-by":"publisher","first-page":"237","DOI":"10.18433\/jpps32867","article-title":"Torsade de Pointes\/QT prolongation associated with antifungal triazoles: a pharmacovigilance study based on the U.S. FDA Adverse Event Reporting System (FAERS)","volume":"25","author":"Yu","year":"2022","journal-title":"J. Pharm. Pharm. Sci."},{"key":"B43","doi-asserted-by":"publisher","first-page":"984572","DOI":"10.3389\/fcvm.2023.984572","article-title":"A case report of sudden cardiac arrest and torsade de pointes induced by the second-generation tyrosine kinase inhibitor dasatinib combined with fluconazole","volume":"10","author":"Yuan","year":"2023","journal-title":"Front. Cardiovasc. Med."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1039867","DOI":"10.3389\/fphar.2022.1039867","article-title":"Pharmacovigilance of triazole antifungal agents: analysis of the FDA adverse event reporting system (FAERS) database","volume":"13","author":"Zhou","year":"2022","journal-title":"Front. Pharmacol."}],"updated-by":[{"DOI":"10.3389\/fphar.2024.1425672","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T00:00:00Z","timestamp":1715817600000}}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1255918\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T14:55:49Z","timestamp":1715871349000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1255918\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,20]]},"references-count":44,"alternative-id":["10.3389\/fphar.2024.1255918"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1255918","relation":{"erratum":[{"id-type":"doi","id":"10.3389\/fphar.2024.1425672","asserted-by":"object"}]},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,20]]},"article-number":"1255918"}}